FDA approves Sandoz’s two denosumab biosimilars
06 Mar 2024
Drug ApprovalOrphan DrugCell TherapyImmunotherapy
Preview
Source: Pharmaceutical Technology
The FDA approval positions Wyost as a treatment to prevent skeletal-related events. Credit: BigPixel Photo / Shutterstock.com.
The US Food and Drug Administration (FDA) has approved SandozSandoz’s Wyost (denosumab-bbdz) and Jubbonti (denosumab-bbdz), marking the introduction of the first FDA-approved denosumab biosimilars.
These biosimilars are authorised to treat all indications of their reference medicines.
With a concentration of 120mg/1.7mL (70mg/mL), Wyost is indicated as interchangeable with its reference medicine, a human monoclonal antibody that acts on the RANKL protein, which is essential for the activation of osteoclasts.
This approval positions Wyost as a treatment to prevent skeletal-related events in patients with multiple myeloma and for those with bone metastases caused by solid tumours.
Wyost is also sanctioned for use in adults and skeletally mature adolescents with giant cell tumours in bone that are either unresectable or where surgical resection could cause significant morbidity.
See Also:A2 Bio’s cell therapy gains FDA orphan drug status for colorectal cancer
Preview
Source: Pharmaceutical Technology
FDA doubles down on patient engagement to support rare disease research
Preview
Source: Pharmaceutical Technology
It is also approved for treating hypercalcaemia of malignancy resistant to bisphosphonate treatment.
Jubbonti is indicated to address several conditions related to bone health.
It is approved for treating high fracture risk in postmenopausal women with osteoporosis, for improving bone mass in men with osteoporosis at similar risk, and for managing glucocorticoid-induced osteoporosis in anyone with this risk.
Jubbonti is also approved to augment bone mass in men at high fracture risk due to undergoing androgen deprivation treatment for non-metastatic prostate cancer, and women receiving adjuvant aromatase inhibitor therapy for breast cancer.
Extensive clinical studies support the latest regulatory approval in the US for these biosimilars and include safety warnings within the labelling.
The approval of Jubbonti is paired with the sanctioning of Sandoz’s Jubbonti Risk Evaluation and Mitigation Strategy (REMS) programme.
The programme is tailored to educate prescribers and patients about potential severe hypocalcaemia risk, particularly in those with advanced chronic kidney disease, including those dependent on dialysis.
Sandoz North America president Keren Haruvi stated: “Sandoz has achieved the first FDA approval for biosimilars to denosumab, a medicine that can address primary and secondary bone loss, such as osteoporosis, as well as cancer-related skeletal events […] disease states that can profoundly reduce the quality of life for patients.”
The latest development comes after SandozSandoz acquired US biosimilar CIMERLI from Coherus BioSciences.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.